Thank you for your inquiry on CMS108, Venous Thromboembolism Prophylaxis. At this time, apixaban is not approved for general medical or surgical VTE prophylaxis. Apixaban is approved for reduction of stroke and systemic embolism risk in patients with nonvalvular atrial fibrillation, treatment for VTE, prevention of recurring VTE, and VTE prophylaxis in patients who have undergone total hip or total knee replacement surgery. Please see FDA package insert list of approved indications https://packageinserts.bms.com/pi/pi_eliquis.pdf .   This is captured in the numerator logic with the following expression if the patient received an oral factor Xa inhibitor and (intersect) they had a prior or current diagnosis of atrial fibrillation of VTE, or (union) they had a hip or knee replacement surgery prior to or with the current encounter. Apixaban is included in the Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment value set (2.16.840.1.113883.3.117.1.7.1.134), which is used for this logic.   "Encounter With VTE Prophylaxis Received From Day of Start of Hospitalization To Day After Admission or Procedure"   union ( "Encounter With Medication Oral Factor Xa Inhibitor Administered on Day of or Day After Admission or Procedure"       intersect ( "Encounter With Prior or Present Diagnosis of Atrial Fibrillation or VTE"           union "Encounter With Prior or Present Procedure of Hip or Knee Replacement Surgery"       )   We continuously monitor FDA approved indications for medications to determine which ones are appropriate for inclusion in value sets. If the FDA-approved indications for Apixaban change in the future to include VTE prophylaxis for additional cohorts of patients, we will consider updates to relevant value sets during the annual review process.